The Colonial Room of the St. Francis Hotel in San Francisco was filled beyond capacity Monday afternoon, and the offices of digital-health seed fund Rock Health were buzzing with hundreds of partygoers just a couple of hours later.
Swiss drugmaker Roche said on Wednesday it had entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents, pertaining to the detection of mutations in the EGFR pathway.
In a laboratory first, Duke researchers have grown human skeletal muscle that contracts and responds just like native tissue to external stimuli such as electrical pulses, biochemical signals and pharmaceuticals.
It didn’t take R. Michael Gill very long to come up with some priorities after Gov.-elect Larry Hogan named him the next Maryland Department of Business and Economic Development secretary last week.
Gill wants to keep McCormick & Co. Inc. (NYSE: MKC) in state. He wants to bring the FBI headquarters to Maryland. And he wants to emphasize customer service in dealing with businesses.
Lockheed Martin Corp. is normally known for big things – tanks, planes, ships, those kinds of projects.
But a new partnership the defense giant has formed with a San Diego company has Lockheed looking at something very, very small.
The ETC (Emerging Technology Centers) www.etcbaltimore.com, Baltimore City’s award-winning technology innovation centers, announced today that the following six companies have been accepted into the AccelerateBaltimore™ 2015 program:
Show me the money, I’m not seeing it here.
According to NVCA, U.S. VC firms raised $29.8B in 2014, making it the best fundraising year since 2007 (’13 was $17.7B). Overall this is good news, but there has not been local traction. Here is the data from NVCA on the D.C. located funds that raised capital in ’14:
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV). The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.
Washington, D.C., Philadelphia, New York — Maryland has a lot of competition for entrepreneurs’ attention. Experts say a tax credit specifically for angel investors could sweeten the deal for entrepreneurs and investors who decide to do business in Maryland.
Establishing an angel investor tax credit will be a top priority for the Greater Baltimore Committee during the state’s upcoming legislative session. GBC sees the tax credit as a way to boost the state’s economy by supporting growing startups that will create jobs and bring new business to Maryland. Investors and adivsors of Baltimore-area startups say the tax credit would not only help startups grow in Maryland, but keep them — and their investors — from laying roots elsewhere.
Sample and assay technologies provider Qiagen NV recently announced the launch of its latest diagnostic TB test– QuantiFERON-TB Gold-Plus (QFT-Plus), subsequent to the product’s receipt of CE Mark in Europe.
QFT-Plus is the fourth generation of the most accurate test used in the diagnosis of tuberculosis (TB) infection. It involves Qiagen’s proprietary QuantiFERON technology which can uniquely identify presymptomatic infections that standard diagnostic technologies fail to detect.